[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes
Source 柳叶刀 Lancetjust now
Summary
Cardiovascular outcomes trials with GLP-1 receptor agonists, which to date have largely comprised peptide analogues of the incretin hormone GLP-1, have evolved…
We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.
Open original- Desk
- Health
- Region
- United Kingdom
- Language
- English
- Item ID
- health-1d503d72
Comments 0 comments
No comments yet. Be the first.